CytoMed Therapeutics Ltd
NASDAQ:GDTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CytoMed Therapeutics Ltd
NASDAQ:GDTC
|
SG |
|
P
|
Polynovo Ltd
SWB:MFJ
|
AU |
|
R
|
Royal Gold Inc
F:RG3
|
US |
|
Cizzle Biotechnology Holdings PLC
F:E7F0
|
UK |
|
Nestle SA
F:NESR
|
CH |
|
Nisshin Seifun Group Inc
TSE:2002
|
JP |
|
SoFi Technologies Inc
NASDAQ:SOFI
|
US |
|
Alcoa Corp
NYSE:AA
|
US |
Intrinsic Value
Is GDTC undervalued or overvalued?
See the intrinsic value estimate for CytoMed Therapeutics Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
GDTC looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with GDTC’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What CytoMed Therapeutics Does
CytoMed Therapeutics is a development-stage biotech company that works on cell-based immunotherapies, mainly for cancer. It is building treatments from immune cells that are meant to attack tumors, with a focus on creating off-the-shelf therapies that can be made from donor material instead of being custom-built for each patient.
- Headquarters
- Singapore SG
- Employees
- 27
- IPO date
- Apr 14, 2023
Earnings Waterfall
CytoMed Therapeutics Ltd
The intrinsic value for CytoMed Therapeutics Ltd (GDTC) under the Base Case is hidden USD.
Compared with the current market price of 0.919 USD, the stock appears hidden.